GURU.Markets stock price, segment price, and overall market index valuation
The company's share price SIGA Technologies Inc.
SIGA Technologies is a company specializing in biohazard therapeutics, specifically its flagship product, TPOXX, used to treat smallpox. Its stock price has skyrocketed on news of disease outbreaks, such as monkeypox, and government procurement.
Share prices of companies in the market segment - Pharma virus
SIGA Technologies specializes in developing solutions to protect against biological and chemical threats, including smallpox treatments. We've classified it in the "Pharmaceuticals (Virology)" segment, which has become particularly important. The chart below reflects the dynamics of this strategically important healthcare sector.
Broad Market Index - GURU.Markets
SIGA Technologies is a commercial pharmaceutical company specializing in drugs to combat viral and biological threats, including smallpox. Its unique niche earns it a spot in the GURU.Markets index. The chart below compares its performance to the market.
Change in the price of a company, segment, and market as a whole per day
SIGA - Daily change in the company's share price SIGA Technologies Inc.
Shares of SIGA, a biodefense specialist, exhibit event-driven volatility. change_co measures reactions to news about virus outbreaks and government procurement of its products. This metric is important for analyzing companies dependent on government contracts on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma virus
SIGA Technologies, Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing this to SIGA's performance, which focuses on smallpox drugs, helps understand its unique risk profile, which is dependent on government contracts and bioterrorism threats.
Daily change in the price of a broad market stock, index - GURU.Markets
SIGA is a biopharmaceutical company specializing in drugs to protect against biological threats such as smallpox. Its business relies on government contracts. The chart below shows overall market volatility, which may make SIGA appear more stable.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization SIGA Technologies Inc.
SIGA, the maker of a smallpox drug, has been in the spotlight over the past year due to global biosecurity threats. Its year-over-year share price performance, shown in the chart, reflects its unique position and the government contracts it receives for its products.
Annual dynamics of market capitalization of the market segment - Pharma virus
SIGA Technologies, Inc. is a commercial pharmaceutical company specializing in solutions to protect against biological threats, including smallpox. Its business is based on government contracts. The chart below illustrates how its unique "defense" niche and dependence on government contracts influence its volatile performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
SIGA, with its smallpox drug, is a unique story. Its stock price is unrelated to the economy, but soars on news of disease outbreaks and government procurement. The chart is a bet on a "black swan" event, one that could lie dormant for years and then deliver huge profits.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization SIGA Technologies Inc.
Heritage, a bank operating in Silicon Valley and its surrounding areas, charts monthly fluctuations reflect the health of the tech sector and the local real estate market. The state of venture capital funding is an important indirect factor.
Monthly dynamics of market capitalization of the market segment - Pharma virus
SIGA Technologies specializes in developing defenses against biological threats, including smallpox. Demand for its products is non-market and depends on government procurement and pandemic preparedness. The dynamics of the biosecurity sector reflect how seriously governments perceive these threats, which directly impacts SIGA's contracts and revenue.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
SIGA Technologies, Inc. is a commercial pharmaceutical company specializing in solutions to combat health threats, specifically an oral antiviral drug for smallpox. Its business relies on government contracts and pandemic preparedness. A broad market chart allows us to assess how its unique niche has made its stock independent of broader trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization SIGA Technologies Inc.
Shares of SIGA Technologies, a developer of biothreat defense systems, follow the rhythm of global health news. Weekly performance is a sensitive indicator of virus outbreaks and government decisions to purchase medications for strategic stockpiles.
Weekly dynamics of market capitalization of the market segment - Pharma virus
SIGA Technologies, operating in the biodefense sector, is heavily dependent on general sentiment and news in this niche. Sudden virus outbreaks or news about government procurement can trigger a surge in the entire sector, creating broad trends. The chart below allows you to compare whether SIGA is leading these movements or simply following the general industry wave of anxiety and preparedness.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
SIGA Technologies shares often live their own lives, defying broader market trends. Global health threats, not inflation data, drive demand for its products. The chart below clearly demonstrates how SIGA can soar on virus news, while the overall market declines due to economic concerns.
Market capitalization of the company, segment and market as a whole
SIGA - Market capitalization of the company SIGA Technologies Inc.
SIGA Technologies' market capitalization chart is a history of the world's preparedness for biothreats. Its dynamics don't follow the market, but rather explode with news of virus outbreaks, such as monkeypox. Each sharp rise reflects investors' assessment of government contracts for its antiviral drug, reflecting how fear and pandemics affect the company's value.
SIGA - Share of the company's market capitalization SIGA Technologies Inc. within the market segment - Pharma virus
SIGA Technologies occupies a unique niche in the biodefense sector; its core product, TPOXX, is essential for strategic government stockpiles. The company's share of the market capitalization of its narrow pharmaceutical segment reacts sharply to viral threats. The chart below clearly illustrates how its share depends on government contracts and the global epidemiological situation.
Market capitalization of the market segment - Pharma virus
SIGA Technologies is a biodefense company developing treatments against deadly viruses like smallpox. The chart below reflects the market capitalization of this highly specialized sector. Its performance is driven not by market cycles, but by government contracts and global health threats.
Market capitalization of all companies included in a broad market index - GURU.Markets
SIGA Technologies is a global biodefense company; its key drug, TPOXX, is purchased by governments to protect against smallpox. The company's market capitalization is not a measure of sales, but a financial reflection of the importance of pandemic preparedness. Its global market share reflects the economic importance of protecting against rare but catastrophic threats.
Book value capitalization of the company, segment and market as a whole
SIGA - Book value capitalization of the company SIGA Technologies Inc.
SIGA Technologies' foundation is its strategic national security stockpile. Its book value reflects the rights to the antiviral drug TPOXX and, more importantly, significant stockpiles of this drug built up under contracts with the US government. The chart below shows how fulfilling these government contracts has strengthened the company's inventory.
SIGA - Share of the company's book capitalization SIGA Technologies Inc. within the market segment - Pharma virus
SIGA Technologies combats viral threats with its highly secure laboratories and production facilities. This specialized infrastructure is its primary physical asset. The chart below shows the company's share of its biodefense capabilities, ready for rapid response.
Market segment balance sheet capitalization - Pharma virus
The graph illustrates the capital-intensive world of pharmaceuticals, but SIGA Technologies occupies a unique niche. Its business is focused on biodefense, and its key product is supplied to the state reserve. This makes its model less dependent on traditional commercial infrastructure, although production still requires significant tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
SIGA Technologies' assets aren't just medicines, but a strategic reserve against biothreats, a physical shield for entire nations. Their flagship product, TPOXX, is held in government reserves. The chart below shows the economic weight of this "doomsday pharmacy," protecting us from global pandemics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - SIGA Technologies Inc.
SIGA's balance sheet consists of its stockpiles of its life-saving drug, TPOXX, and funding for research. The market is assessing not only this, but also the company's unique status as a supplier to the US Strategic Biothreat Reserve. The chart below shows the premium investors are paying for this virtually guaranteed government demand.
Market to book capitalization ratio in a market segment - Pharma virus
SIGA Technologies specializes in developing solutions against biological threats, specifically the smallpox virus. Its value lies in its unique products and government contracts. This chart shows how its market valuation, which depends on government contracts and the epidemiological situation, correlates with its tangible assets.
Market to book capitalization ratio for the market as a whole
SIGA Technologies specializes in solutions to protect against biological threats, including an approved smallpox drug. The company's value lies not in its manufacturing facilities, but in its patents and long-term government contracts for strategic reserve supplies. The chart clearly demonstrates how investors value this unique business model, where capitalization is built on IP and government contracts.
Debts of the company, segment and market as a whole
SIGA - Company debts SIGA Technologies Inc.
The financial strategy of SIGA Technologies, a biodefense developer, is directly linked to government contracts. This chart shows how the company manages its commitments to finance the production and supply of vital drugs like TPOXX for national stockpiles, ensuring preparedness for health emergencies.
Market segment debts - Pharma virus
SIGA Technologies specializes in drugs against biological threats, primarily smallpox. The company's business relies heavily on government contracts to create strategic stockpiles. Its debt policy reflects the stability of these contracts and its investment in research. This chart allows us to assess the company's financial stability in its highly specialized niche.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio SIGA Technologies Inc.
SIGA Technologies, whose core business is government contracts for biosecurity products, has a predictable cash flow. This chart shows how the company uses debt financing to scale production and research. The debt level here is an indicator of confidence in future government contracts and emergency preparedness.
Market segment debt to market segment book capitalization - Pharma virus
SIGA Technologies occupies a unique niche in the biosecurity sector, supplying its key antiviral drug to governments for national stockpiles. This chart compares the company's debt load to the total book value of the entire pharmaceutical sector. It helps investors understand how SIGA's financial strategy, dependent on large government contracts, differs from that of traditional pharmaceutical companies.
Debt to book value of all companies in the market
SIGA Technologies, which specializes in biological defense solutions, frequently relies on government contracts. This business model can ensure stable cash flow, reducing reliance on debt financing. The chart below illustrates market-wide trends in debt levels, allowing one to assess the conservative nature of SIGA's financial policy.
P/E of the company, segment and market as a whole
P/E - SIGA Technologies Inc.
This metric for SIGA Technologies illustrates the valuation of a company occupying a unique niche in the biodefense sector. Its primary revenue comes from government contracts for smallpox vaccines. The chart shows how investors assess the likelihood of new threats and government procurement, making the valuation highly event-driven rather than reliant on stable profits.
P/E of the market segment - Pharma virus
SIGA Technologies specializes in the development and commercialization of medical solutions to combat serious viral diseases, including smallpox. Its flagship drug is a key component of the US Strategic National Stockpile. This chart represents the average valuation for the infectious disease-focused pharmaceutical sector, where government contracts and pandemic preparedness play a significant role.
P/E of the market as a whole
SIGA Technologies specializes in biodefense products, particularly smallpox treatments. Demand for its products is driven not by economic cycles, but by government procurement and pandemic threats. This indicator measures the overall health of the economy. It helps understand whether SIGA is operating in its own reality or whether its valuation as a biotech company is also subject to general market fluctuations.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company SIGA Technologies Inc.
For SIGA Technologies, a biodefense solutions company, this chart shows analyst expectations for future revenue related to government contracts and demand for their antiviral drugs. Fluctuations in the chart may reflect changes in the epidemiological situation and forecasts for new drug supply contracts.
%20P%2FE%20SIGA%20Technologies%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-SIGA-Technologies-Inc.&v=1772692055772 "Chart of the company's future (projected) P/E SIGA Technologies Inc.")
Future (projected) P/E of the market segment - Pharma virus
SIGA Technologies specializes in antiviral drugs, including the vital TPOXX used to combat smallpox. The data presented here represents the average estimate of future profitability for pharmaceutical companies. Analyzing SIGA's position against this backdrop helps us understand whether the market is pricing in the potential for new government contracts or whether it sees greater risks than its competitors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772692055789 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
SIGA Technologies operates in the biodefense sector, where demand is driven not by general economic cycles but by specific health threats. Therefore, unlike most companies, its success depends less on the general optimism of investors, as reflected in this chart, and more on government preparedness for pandemic risks.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772692055801 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit SIGA Technologies Inc.
SIGA Technologies specializes in biohazard defense products, their flagship product being the smallpox drug TPOXX. The financial results in this chart reflect not consistent pharmacy sales, but rather large government contracts to replenish strategic reserves. The sharp profit spikes here are the result of contracts for the supply of vital medications.
Profit of companies in the market segment - Pharma virus
SIGA Technologies is a public health advocate focused on developing treatments against biothreats such as smallpox. The company's success is inextricably linked to the overall health of its highly specialized segment. This chart demonstrates how much the industry's profitability depends on global threats and government orders to stockpile strategic drugs during periods of calm.
Overall market profit
SIGA Technologies develops and supplies products to protect against biological threats, its primary product being a smallpox treatment. Its primary customer is the US government. Demand for the company's products is driven by government biosecurity programs and is independent of general economic cycles, as reflected in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company SIGA Technologies Inc.
SIGA Technologies specializes in antiviral drugs, and its financial future is closely tied to government contracts for drugs like TPOXX. This chart shows analyst consensus earnings forecasts, which investors use to assess the likelihood of new orders and potential demand in the event of epidemiological threats.
%20profit%20of%20the%20company%20SIGA%20Technologies%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-SIGA-Technologies-Inc.&v=1772692055848 "Graph of future (projected) profit of the company SIGA Technologies Inc.")
Future (predicted) profit of companies in the market segment - Pharma virus
SIGA Technologies safeguards global security by developing antiviral drugs like TPOXX for smallpox. This chart reflects future profitability expectations for the entire biodefense sector. For SIGA, whose business relies heavily on government contracts and pandemic preparedness, this trend allows us to assess how aggressively governments will replenish their stockpiles.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772692055850 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
SIGA Technologies specializes in biological defense solutions, including smallpox treatments. The company's business is weakly dependent on general economic cycles, as reflected in its total revenue forecast. Its revenue is determined by government contracts and the level of global health threats, rather than by consumer market conditions. Therefore, SIGA's performance may deviate significantly from general trends.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772692055859 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - SIGA Technologies Inc.
SIGA Technologies specializes in biodefense, and its key product, TPOXX, is a smallpox treatment. The company's revenue is heavily dependent on large government contracts to build strategic stockpiles. This chart shows how investors assess the potential for future orders: a high score indicates confidence in new contracts, while a low score indicates a current lack of them.
P/S market segment - Pharma virus
SIGA Technologies specializes in biothreat defense, and its key product is the smallpox drug TPOXX. This chart shows the average price-to-sales ratio for biopharmaceutical companies. It helps assess whether SIGA's premium or discount relative to its competitors is justified by its unique market niche and dependence on large government contracts.
P/S of the market as a whole
SIGA Technologies is a biosecurity company with a key smallpox drug. Its revenue is heavily dependent on government contracts, creating a unique risk profile. This chart compares the valuation of this specific revenue with the overall market and helps understand how investors view the company's strategic importance.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company SIGA Technologies Inc.
SIGA Technologies specializes in products to protect against bioterrorism and viral threats, with its key product being the smallpox drug TPOXX. The company's future depends largely on government contracts and strategic stockpile replenishment programs. The data presented reflects the market valuation of the company based on forecasts of future contracts and deliveries.
%20P%2FS%20SIGA%20Technologies%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-SIGA-Technologies-Inc.&v=1772692055890 "The graph of the company's future (projected) P/S SIGA Technologies Inc.")
Future (projected) P/S of the market segment - Pharma virus
SIGA Technologies is a key player in the biodefense market, known for its smallpox treatment. The data in the chart reflects average market expectations for future sales in its highly specialized field. This allows us to assess how highly investors value SIGA's revenue potential from government contracts compared to other companies operating in the biodefense sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772692055918 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
SIGA Technologies operates in the biosecurity sector, where revenue depends not on general economic cycles but on the world's preparedness for threats. While this indicator reflects investors' confidence in sales growth across the economy, SIGA's business is driven by government contracts for smallpox protection products. This exemplifies how the sector operates by its own rules.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772692055926 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales SIGA Technologies Inc.
SIGA Technologies is a biopharmaceutical company whose flagship product, the antiviral drug TPOXX, is purchased by governments for strategic reserves. This chart shows that the company's revenue can be irregular and volatile. Major sales spikes are directly related to the conclusion and execution of large government procurement contracts.
Sales of companies in the market segment - Pharma virus
SIGA Technologies specializes in developing solutions to combat serious viral diseases that pose a threat to national security, such as smallpox. Its core product, TPOXX, is a key component of the US strategic stockpile. This chart shows the segment's total revenue, allowing investors to assess the growth of the biodefense and pharmaceuticals market.
Overall market sales
SIGA Technologies operates in the biosecurity sector, creating protection against global health threats. This chart reflects overall economic activity, but SIGA's business operates by different rules. Its revenue depends not on consumer demand, but on government contracts and global pandemic preparedness. This makes the company independent of general market cycles.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company SIGA Technologies Inc.
SIGA Technologies specializes in biological defense solutions, including the smallpox drug TPOXX. The company's sales are heavily dependent on government contracts and pandemic preparedness programs. This chart visualizes expert forecasts for demand for vital protective equipment in an uncertain world.
%20sales%20of%20the%20company%20SIGA%20Technologies%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-SIGA-Technologies-Inc.&v=1772692055968 "Schedule of future (projected) sales of the company SIGA Technologies Inc.")
Future (projected) sales of companies in the market segment - Pharma virus
SIGA Technologies is at the forefront of biosecurity, developing drugs to protect against deadly pathogens. The company's key product is TPOXX, approved for the treatment of smallpox. This chart shows projected revenue for the entire pharmaceutical segment related to viral protection. Will focusing on such niches drive above-market growth?
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772692055970 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
SIGA Technologies develops solutions against smallpox and other viral threats, making its business dependent on government healthcare spending. This chart shows the dynamics of overall business activity expectations. Increasing overall sales forecasts may signal a willingness by governments and corporations to invest more in biodefense, expanding SIGA's market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772692055973 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality SIGA Technologies Inc.
SIGA Technologies specializes in healthcare solutions, specifically antiviral drugs for government contracts. The company's profitability is directly dependent on large government contracts. This chart demonstrates how fulfilling such contracts impacts the company's ability to generate profits, reflecting demand cycles for strategic medical products.
Market segment marginality - Pharma virus
SIGA Technologies specializes in antiviral drugs, primarily TPOXX, an anti-smallpox drug purchased by governments for strategic stockpiles. This chart reflects the average profitability in the pharmaceutical industry. SIGA's profitability is directly dependent on large government contracts, not retail sales, which can lead to high but variable margins compared to this metric.
Market marginality as a whole
SIGA Technologies focuses on developing solutions to combat viral threats, including smallpox. The company's profitability is heavily dependent on government contracts and the epidemiological situation. This chart helps us assess how its highly specialized business, dependent on global health threats, deviates from the overall corporate profitability picture.
Employees in the company, segment and market as a whole
Number of employees in the company SIGA Technologies Inc.
SIGA Technologies specializes in healthcare solutions, and the dynamics on this chart directly reflect its operational activity. An increase in this indicator may signal the signing of major government contracts requiring expanded production and research, particularly for its key antiviral drug, TPOXX.
Share of the company's employees SIGA Technologies Inc. within the market segment - Pharma virus
SIGA Technologies is a global champion of biothreats, developing life-saving treatments like TPOXX against smallpox. The company operates in a niche where the size of its staff, rather than its unique expertise, is crucial. This chart shows the proportion of antiviral defense experts concentrated at SIGA, highlighting its critical role as an employer in the national security sector.
Number of employees in the market segment - Pharma virus
SIGA Technologies specializes in the development and commercialization of drugs to combat serious viral diseases, including smallpox. Headcount fluctuations, as reflected in the graph, often correlate with clinical trial phases, government drug supply contracts, or expanded research into emerging health threats.
Number of employees in the market as a whole
SIGA Technologies' business is focused on biodefense and is not dependent on the classic economic cycles reflected in this chart. While overall employment indicates a healthy commercial sector, demand for SIGA products is driven by government orders and preparedness for global health threats, representing a strategic rather than cyclical economic sector.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company SIGA Technologies Inc. (SIGA)
SIGA Technologies' high value stems from its intellectual property—patents for biodefense drugs. This chart shows how the market values scientific potential rather than labor force. The company doesn't require a large staff for production or sales, so its capitalization, based on unique developments, is distributed among a small team of scientists and managers.
%20of%20the%20company%20SIGA%20Technologies%20Inc.%20(SIGA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-SIGA-Technologies-Inc.-SIGA&v=1772692056073 "Chart of market capitalization per employee (in thousands of dollars) of the company SIGA Technologies Inc. (SIGA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
SIGA Technologies is a key player in the biosecurity market, focused on protecting against deadly pathogens like smallpox. The company's success depends on breakthrough research and government contracts, not on the size of its staff. This chart shows how highly the market values their intellectual capital per team member.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772692056080 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
SIGA Technologies specializes in developing solutions against virus threats, where intellectual property plays a key role. This chart shows how the market values scientific potential. For SIGA, the high value per employee reflects the value of their patents and developments, which could generate significant profits if successfully commercialized.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772692056083 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company SIGA Technologies Inc. (SIGA)
SIGA Technologies is at the forefront of the fight against viral threats, developing antiviral drugs. This chart translates their scientific breakthroughs into business terms, showing how much net profit each employee generates. It's a direct indicator of how effectively their R&D team translates research into commercially successful and life-saving treatments.
%20Chart%20SIGA%20Technologies%20Inc.%20(SIGA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-SIGA-Technologies-Inc.-SIGA&v=1772692056099 "Company Profit Per Employee (in thousands of dollars) Chart SIGA Technologies Inc. (SIGA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
SIGA Technologies is a biotech company whose main product is TPOXX, a smallpox treatment (and mpox). This chart shows the benchmark for the Pharma (Viruses) sector. Average earnings per employee in this sector are extremely volatile. The benchmark reflects a "one-hit wonder": the sector relies on government contracts (bioterrorism reserves), which are driven by geopolitics rather than R&D.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772692056104 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
SIGA Technologies specializes in antiviral drugs, and their flagship product, TPOXX (for treating smallpox), is of strategic importance to government reserves. Biopharma is a high-R&D industry, but a successful patent generates colossal revenue with a relatively small staff. This chart shows how much profit a single employee can generate if their work is patented.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772692056110 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee SIGA Technologies Inc. (SIGA)
For SIGA Technologies, this chart shows how revenue from sales of vital antiviral drugs, often under government contracts, correlates with the size of the team. Sharp peaks can indicate the successful completion of a major contract, highlighting the ability of a small team of experts to deliver colossal financial results.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-SIGA-Technologies-Inc.-SIGA&v=1772692056114 "Sales chart per company employee SIGA Technologies Inc. (SIGA)")
Sales per employee in the market segment - Pharma virus
SIGA Technologies (SIGA) is a biodefense company whose flagship product (TPOXX) is purchased by governments for smallpox protection. This chart shows their performance relative to the sector. SIGA's business is extremely volatile: large but infrequent government contracts generate huge revenues, which are distributed among a relatively small staff of scientists and managers, dramatically increasing productivity.
Sales per employee for the market as a whole
SIGA specializes in solutions against serious viral threats, and their flagship product is TPOXX. For biotech, this chart shows operating leverage. Years of research require a team of experts (costs), but the success of a single drug and large government contracts (as with TPOXX) can generate enormous revenue, disproportionate to the staff.
Short shares by company, segment and market as a whole
Shares shorted by company SIGA Technologies Inc. (SIGA)
SIGA Technologies (SIGA) is a company whose fate depends on threats. They specialize in biodefense, and their flagship product, TPOXX, is a key smallpox drug purchased by governments. This figure reflects market skepticism. Perhaps investors are hesitant to renew government contracts or believe that current biothreats are overvalued, reducing demand for TPOXX?
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-SIGA-Technologies-Inc.-SIGA&v=1772692056140 "Short Shares Chart for the Company SIGA Technologies Inc. (SIGA)")
Shares shorted by market segment - Pharma virus
SIGA Technologies is a highly specialized company whose survival depends on government contracts for TPOXX (a smallpox drug) for the strategic biodefense reserves. This chart reflects bets against the entire biodefense sector. Its rise indicates that investors are hesitant to extend major government contracts or believe the threat of pandemics (and, consequently, government procurement) is declining.
Shares shorted by the overall market
SIGA Technologies (SIGA) specializes in drugs to combat the threats of bioterrorism and pandemics, with their key product being a smallpox treatment (TPOXX). Their business relies on government contracts. This chart shows the overall market fear. Although SIGA's business is not dependent on the economy, during periods of panic, investors may take profits even in "defensive" positions or fear changes in government budgets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator SIGA Technologies Inc. (SIGA)
SIGA Technologies produces TPOXX, an antiviral drug approved for the treatment of smallpox (and used against monkeypox). The company's stock is a pure bet on "pandemic fear." This chart measures that fear. It shows when the stock is "overbought" on outbreak news or "oversold" when the news cycle is calm.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-SIGA-Technologies-Inc.-SIGA&v=1772692056165 "RSI 14 indicator chart for the company's stock SIGA Technologies Inc. (SIGA)")
RSI 14 Market Segment - Pharma virus
SIGA Technologies specializes in biodefense solutions. Their flagship product, TPOXX, is an approved treatment for smallpox (and monkeypox). This chart measures the overall momentum in the biodefense pharmaceutical sector. It helps determine whether the entire segment is overheated amid news of disease outbreaks.
RSI 14 for the overall market
SIGA Technologies (SIGA) produces smallpox treatments, primarily for government contracts. This chart is less important to the company than pandemic news. Market euphoria or panic don't affect demand. However, panic related to biothreats could trigger a sharp increase in demand for its products from governments, creating its own cycle.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SIGA (SIGA Technologies Inc.)
SIGA Technologies is a biopharmaceutical company specializing in antiviral drugs. Their key product is TPOXX, approved for the treatment of smallpox and used against monkeypox. This chart shows the average 12-month forecast from analysts. It reflects their assessment of future government orders for TPOXX for the national stockpile.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SIGA-SIGA-Technologies-Inc.&v=1772692056193 "A chart showing analyst consensus forecasts for the expected stock price. SIGA (SIGA Technologies Inc.)")
The difference between the consensus estimate and the actual stock price SIGA (SIGA Technologies Inc.)
SIGA Technologies is a niche biodefense company. Its key product, TPOXX, is the only approved treatment for smallpox (and monkeypox). Its client is the US Government (strategic reserve). This chart shows the difference between the consensus forecast and the price. It reflects analysts' confidence in the stability of these government contracts.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SIGA-SIGA-Technologies-Inc.&v=1772692056203 "A chart showing the difference between the consensus forecast and the actual stock price. SIGA (SIGA Technologies Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
SIGA Technologies is the company whose flagship product, TPOXX (Tecovirimat), is the only approved treatment for smallpox. It serves as a "safety net" for governments against bioterrorism. This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe government procurement of this strategic drug is sustainable.
Analysts' consensus forecast for the overall market share price
SIGA Technologies is a one-pronged biotech company. They produce TPOXX, the only cure for smallpox (and monkeypox). Their client is the government budget. This chart, which measures overall market sentiment, has no effect on them. Their business isn't about the economy, but about pandemic fears and government procurement.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index SIGA Technologies Inc.
SIGA Technologies is a bio-shield. Their core business is a single drug, TPOXX, which is a countermeasure against smallpox and monkeypox and is purchased by governments (primarily the US) for strategic stockpiles. This chart is a fear indicator. It likely aggregates their ability to secure new government contracts and spikes on news of any outbreaks of these viruses.
AKIMA Market Segment Index - Pharma virus
SIGA (SIGA) is a strategic biotech; the company owns (and sells to governments) a key antiviral drug (TPOXX), the only approved treatment for smallpox (and monkeypox). This summary metric measures R&D. The graph shows the segment average. This benchmark: how does this unique monopoly (B2G, biodefense) differentiate SIGA from the average pharma company?
The AKIM Index for the overall market
SIGA Technologies is a company specializing in health security. It produces TPOXX, an antiviral drug for smallpox (and monkeypox). This chart, which reflects the market average, is a backdrop. It helps assess how this business, dependent on government stockpiles and biosecurity threats, fares against the backdrop of overall macroeconomic fluctuations.
